The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.138%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,435.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Declaration

3 Feb 2017 13:30

RNS Number : 0142W
Indivior PLC
03 February 2017
 

Indivior PLC (the 'Company') - Director Declaration

The Board of Indivior PLC announces that Cary Claiborne has stepped down from his role as Chief Financial Officer in order to pursue other opportunities. The Board of Indivior PLC has appointed Mark Crossley to succeed Cary as CFO.

Mark is currently Chief Strategy Officer of Indivior and was previously Finance Director of the Reckitt Benckiser Pharmaceuticals division prior to the demerger.

Cary will assist with the transition over the coming weeks ahead of the scheduled release of Full Year Results on February 22. As part of the transition, we expect that Cary will step down from the Board and will be replaced by Mark in due course.

Shaun Thaxter, Chief Executive Officer of Indivior PLC, paid tribute to Cary's contribution to the Company during his tenure as Chief Financial Officer from 2014-2017:

"Cary joined us to bring public company experience to the demerger process and the establishment of Indivior as a separate, independent, listed company. He has managed through the complexities of the demerger and separation from Reckitt Benckiser, and the set-up of Indivior, including establishing corporate reporting, internal audit, tax, treasury and external audit; he has also overseen the global implementation of SAP. Throughout these many changes, the Company has delivered strong financial performance and provided transparency to our shareholders. We thank Cary for his many contributions to the successful evolution of Indivior so far and wish him well for the next phase of his career."

Mark was appointed to his current position as Chief Strategy Officer in October 2014. He joined the Company in 2012 as the Global Finance Director with responsibilities for Finance, Information Systems and Procurement. Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight year career with various operational and staff assignments in the United States Coast Guard. Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA. He is a National Association of Corporate Directors Leadership Fellow.

Thaxter continued, "We welcome Mark Crossley to the role of Chief Financial Officer and look forward to benefiting from his experience and knowledge of the business in leading the finance function into the next phase of Indivior's development."

The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Mark Crossley's appointment.

 

Media Contacts

Tulchan Communications

+44 207 353 4200

Stephen Malthouse

Jonathan Sibun

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCOKNDKNBKDCBK
Date   Source Headline
25th Jan 20242:30 pmRNSDirector/PDMR Shareholding - Correction
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSTransaction in Own Shares
19th Jan 20243:54 pmRNSNotice of Results
19th Jan 20247:00 amRNSTransaction in Own Shares
18th Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 20247:00 amRNSTransaction in Own Shares
16th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSTransaction in Own Shares
12th Jan 20247:00 amRNSTransaction in Own Shares
11th Jan 20247:00 amRNSTransaction in Own Shares
10th Jan 20247:00 amRNSTransaction in Own Shares
9th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20247:00 amRNSTransaction in Own Shares
5th Jan 20249:15 amRNSHolding(s) in Company
5th Jan 20247:00 amRNSTransaction in Own Shares
4th Jan 20247:00 amRNSTransaction in Own Shares
3rd Jan 20247:00 amRNSTransaction in Own Shares
2nd Jan 20249:00 amRNSTotal Voting Rights
29th Dec 20237:00 amRNSTransaction in Own Shares
28th Dec 20237:00 amRNSTransaction in Own Shares
27th Dec 20237:00 amRNSTransaction in Own Shares
22nd Dec 202312:42 pmRNSHolding(s) in Company
22nd Dec 202311:46 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSTransaction in Own Shares
21st Dec 202310:33 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSTransaction in Own Shares
20th Dec 20237:00 amRNSIndivior Settles Patent Dispute with Actavis
20th Dec 20237:00 amRNSTransaction in Own Shares
19th Dec 20237:00 amRNSTransaction in Own Shares
18th Dec 20237:00 amRNSTransaction in Own Shares
15th Dec 20237:00 amRNSTransaction in Own Shares
14th Dec 20237:00 amRNSTransaction in Own Shares
13th Dec 20237:00 amRNSTransaction in Own Shares
12th Dec 202312:36 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSTransaction in Own Shares
11th Dec 20237:00 amRNSTransaction in Own Shares
8th Dec 20237:00 amRNSTransaction in Own Shares
7th Dec 20237:00 amRNSTransaction in Own Shares
6th Dec 20237:00 amRNSTransaction in Own Shares
5th Dec 20232:06 pmRNSINDV Prevails in Striking Claims in UK Litigation
5th Dec 20237:00 amRNSTransaction in Own Shares
4th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20238:51 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
30th Nov 20237:00 amRNSTransaction in Own Shares
29th Nov 20237:00 amRNSTransaction in Own Shares
28th Nov 20237:00 amRNSTransaction in Own Shares
27th Nov 20237:00 amRNSTransaction in Own Shares
24th Nov 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.